

Drug Monograph

Drug Name: **Gvoke® (glucagon) kit**
 Drug Class: **Endocrine and Metabolic Agents: Agents for Hypoglycemia**
 Prepared For: MO HealthNet
 Prepared By: Conduent

☒ **New Criteria**

☐ **Revision of Existing Criteria**

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Gvoke is now available in a kit containing one single-dose sterile syringe and one single-doses vial containing 1 mg of glucagon in 0.2 mL of solution.

Manufacturer: Distributed by: Xeris Pharmaceuticals, Inc., Chicago, IL 60601.

Indications: Gvoke is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages 2 years and above.

Costs: \$289.22 per kit. Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List as non-preferred.

Status Recommendation: ☐ Clinical Edit ☐ PA Required
☐ Open Access ☒ PDL

Type of PA Criteria: ☐ Appropriate Indications ☒ Non-Preferred
☐ No PA Required ☐ Preferred

Prepared by: April Ash, PharmD
 Date: December 30, 2021